37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcinoma
37. 中/高危转移性肾细胞癌一线治疗方案中,纳武利尤单抗+伊匹木单抗联合治疗与免疫肿瘤联合酪氨酸激酶抑制剂联合治疗的成本效益分析
期刊:Cancer Cell International
影响因子:6
doi:10.1186/s12935-022-02777-7
Iqbal, Muhammad Javed; Javed, Zeeshan; Herrera-Bravo, Jesús; Sadia, Haleema; Anum, Faiza; Raza, Shahid; Tahir, Arifa; Shahwani, Muhammad Naeem; Sharifi-Rad, Javad; Calina, Daniela; Cho, William C; Ebrahimi, Hedyeh; Berardi, Andrea; Smare, Caitlin; Pavlidou, Eleni; Guttenplan, Sarah B; Eiffert, Sam; Rosenblatt, Lisa; Kurt, Murat; Yin, Xin; Chehrazi-Raffle, Alexander